Cinclus Pharma Holding AB
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
- Conditions
- GERD (Gastroesophageal Reflux Disease)
- Interventions
- Drug: Linaprazan glurate 50 mg Twice Daily (BID)Drug: Linaprazan Glurate 50 mg Once Daily (QD)Drug: Lansoprazole 30 mg Once Daily (QD)
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Cinclus Pharma Holding AB
- Target Recruit Count
- 500
- Registration Number
- NCT07037875
- Locations
- 🇺🇸
Del Sol Research Management, LLC, Tucson, Arizona, United States
🇺🇸Gastro Care Institute, Lancaster, California, United States
🇺🇸Rocky Mountain Gastroenterology Associates - Littleton, Littleton, Colorado, United States
Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects
- Conditions
- GERD
- Interventions
- Drug: linaprazan glurate 25 mg QDDrug: linaprazan glurate 50 mg QDDrug: linaprazan glurate 75 mg QDDrug: linaprazan glurate 25 mg BIDDrug: linaprazan glurate 50 mg BIDDrug: linaprazan glurate 75 mg BID
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Cinclus Pharma Holding AB
- Target Recruit Count
- 75
- Registration Number
- NCT05742984
- Locations
- 🇸🇮
CRS d.o.o,Ukmarjeva ulica 6, Ljubljana, Slovenia
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
- Conditions
- TolerabilitySafety IssuesPharmacokineticsDrug Interaction
- Interventions
- Drug: Drug drug interaction (DDI) - Midazolam (Part 2)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Cinclus Pharma Holding AB
- Target Recruit Count
- 35
- Registration Number
- NCT05633147
- Locations
- 🇸🇪
CTC Clinical Trials Consultants AB, Uppsala, Sweden
Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation
- Conditions
- SafetyPharmacokineticsBioavailability
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Cinclus Pharma Holding AB
- Target Recruit Count
- 67
- Registration Number
- NCT05627518
- Locations
- 🇸🇮
CRS d.o.o., Ljubljana, Ukmarjeva Ulica 6, Slovenia
News
Cinclus Pharma Launches Phase III Trial for Novel GERD Treatment Targeting European Market
Cinclus Pharma has initiated the HEEALING 1 Phase III study to evaluate linaprazan glurate for treating erosive gastroesophageal reflux disease (GERD) following positive regulatory feedback.